Business
Faron Announces Acceptance of Two Studies Involving Bexmarilimab, One of Them as an Oral Presentation, at the 19th International Congress of Immunology (IUIS) 2025
TURKU, FI / ACCESS Newswire / July 9, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - The oral presentation and poster showcase bexmarilimab's dual attack on cancer with new mechanistic data from clinical studies TURKU, FINLAND - Faron Pharmaceuticals ...
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"TURKU, FI / ACCESS Newswire / July 9, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - The oral presentation and poster showcase bexmarilimab's dual attack on cancer with new mechanistic data from clinical studies","length":221,"tagName":"p"},{"type":"text","content":"TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunological pathways, today announced the acceptance of two studies involving its lead candidate, bexmarilimab, for presentation at the 19th IUIS International Congress of Immunology in Vienna, Austria, from August 17-22, 2025.","length":391,"tagName":"p"},{"type":"text","content":"The oral presentation will feature new translational data from the Phase 1/2 BEXMAB clinical study in myelodysplastic syndrome (MDS). The second study, accepted as a poster, details the identification of secreted Clever-1 (sClever-1) as a key driver of immune suppression and immunotherapy resistance. Together, these presentations underscore the growing body of evidence supporting bexmarilimab's mechanism of action.","length":422,"tagName":"p"},{"type":"text","content":"The oral presentation, entitled ‘Dual Mechanisms of Clever-1 Inhibition with Bexmarilimab Plus Azacitidine in Myelodysplastic Syndrome: Translational Insights from the Phase 1/2 BEXMAB Study,' will be presented by Faron's Chief Scientific Officer, Dr. Maija Hollmén. The BEXMAB study is a Phase I/II trial investigating bexmarilimab with standard of care in patients with aggressive hematological malignancies. The study provides insights into how directly targeting the Clever-1 receptor, which is highly expressed in acute myeloid leukemia (AML) and MDS, ignite an immune response, and make current treatments more effective.","length":635,"tagName":"p"},{"type":"text","content":"Dr. Maija Hollmén, senior author of both studies, MediCity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland , said, "The BEXMAB data provides translational insights into bexmarilimab's dual impact in a clinical setting, while our sClever-1 findings elucidate a fundamental mechanism of systemic immune suppression. Showing that bexmarilimab can block sClever-1 release suggests our drug candidate fights cancer on two fronts: reprogrammin...